Who are MN rgp120/HIV-1 and GNE8 rgp120/HIV-1's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mn-rgp120-hiv-1-and-gne8-rgp120-hiv-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (MN rgp120/HIV-1 and GNE8 rgp120/HIV-1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV-1 vaccine. Area: Immunology / Infectious Disease.

phase 3 HIV-1 vaccine gp120 (HIV-1 envelope glycoprotein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (MN rgp120/HIV-1 and GNE8 rgp120/HIV-1) — National Institute of Allergy and Infectious Diseases (NIAID). MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 TARGET	MN rgp120/HIV-1 and GNE8 rgp120/HIV-1	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	HIV-1 vaccine	gp120 (HIV-1 envelope glycoprotein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV-1 vaccine class)

National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/mn-rgp120-hiv-1-and-gne8-rgp120-hiv-1. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab